Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

J Ford; E Cummins; P Sharma; A Elders; F Stewart; R Johnston; P Royle; R Jones; C Mulatero; R Todd; G Mowatt

doi:10.3310/hta17290

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

Abstract

Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.

Original language	English
Pages (from-to)	1-386
Number of pages	386
Journal	Health Technology Assessment
Volume	17
Issue number	29
DOIs	https://doi.org/10.3310/hta17290
Publication status	Published - Jul 2013

Keywords

Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents
Bone Neoplasms
Breast Neoplasms
Cost-Benefit Analysis
Female
Humans
Lung Neoplasms
Male
Models, Economic
Prostatic Neoplasms
Quality-Adjusted Life Years
Randomized Controlled Trials as Topic

Access to Document

10.3310/hta17290

Cite this

Ford, J., Cummins, E., Sharma, P., Elders, A., Stewart, F., Johnston, R., Royle, P., Jones, R., Mulatero, C., Todd, R., & Mowatt, G. (2013). Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 17(29), 1-386. https://doi.org/10.3310/hta17290

@article{79ac2c0142744d03b1d36bda1c9a2688,

title = "Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours",

abstract = "Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.",

keywords = "Antibodies, Monoclonal, Humanized, Bone Density Conservation Agents, Bone Neoplasms, Breast Neoplasms, Cost-Benefit Analysis, Female, Humans, Lung Neoplasms, Male, Models, Economic, Prostatic Neoplasms, Quality-Adjusted Life Years, Randomized Controlled Trials as Topic",

author = "J Ford and E Cummins and P Sharma and A Elders and F Stewart and R Johnston and P Royle and R Jones and C Mulatero and R Todd and G Mowatt",

year = "2013",

month = jul,

doi = "10.3310/hta17290",

language = "English",

volume = "17",

pages = "1--386",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "National Co-ordinating Centre for HTA",

number = "29",

}

Ford, J, Cummins, E, Sharma, P, Elders, A, Stewart, F, Johnston, R, Royle, P, Jones, R, Mulatero, C, Todd, R & Mowatt, G 2013, 'Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours', Health Technology Assessment, vol. 17, no. 29, pp. 1-386. https://doi.org/10.3310/hta17290

TY - JOUR

T1 - Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

AU - Ford, J

AU - Cummins, E

AU - Sharma, P

AU - Elders, A

AU - Stewart, F

AU - Johnston, R

AU - Royle, P

AU - Jones, R

AU - Mulatero, C

AU - Todd, R

AU - Mowatt, G

PY - 2013/7

Y1 - 2013/7

N2 - Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.

AB - Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.

KW - Antibodies, Monoclonal, Humanized

KW - Bone Density Conservation Agents

KW - Bone Neoplasms

KW - Breast Neoplasms

KW - Cost-Benefit Analysis

KW - Female

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Models, Economic

KW - Prostatic Neoplasms

KW - Quality-Adjusted Life Years

KW - Randomized Controlled Trials as Topic

U2 - 10.3310/hta17290

DO - 10.3310/hta17290

M3 - Article

C2 - 23870108

VL - 17

SP - 1

EP - 386

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 29

ER -